Search
Coagulation Factor IX Human
go.drugbank.com/drugs/DB13152ApprovedInvestigationalFactor IX (or Christmas factor) is one of the serine proteases of the coagulation system; it belongs to peptidase family S1. Deficiency of this protein causes hemophilia B.
Mixtures: COFACT 250 IU/10 ML IV ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 1 ADET, COFACT 500 IU/20 ML IV ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 1 ADETCategories: coagulation factor IX, II, VII and X in combinationEstradiol valerate
go.drugbank.com/drugs/DB13956ApprovedInvestigationalVet approved[DB00783] is commonly produced with an ester side-chain as endogenous estradiol has very low oral bioavailability on its own (2-10%). … The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle.
Mixtures: DIVINA 2 MG + 2 MG /10 MG TABLET, 21 ADET, DIVINA 2 MG + 2 MG /10 MG TABLET, 21 ADETCategories: P-glycoprotein substrates, Cytochrome P-450 SubstratesDapsone
go.drugbank.com/drugs/DB00250ApprovedInvestigationalIt is also used with pyrimethamine in the treatment of malaria. (From Martindale, The Extra Pharmacopoeia, 30th ed, p157-8) … A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae.
Mixtures: Dapsone 6% / Niacinamide 2% / Spironolactone 5%, Dapsone 8.5% / Niacinamide 2% / Spironolactone 5%Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 InducersNavtemadlin
go.drugbank.com/drugs/DB15299InvestigationalNavtemadlin (AMG-232) is under investigation in clinical trial NCT03041688 (MDM2 Inhibitor AMG-232 and Decitabine in Treating Patients With Relapsed, Refractory, or Newly-Diagnosed Acute Myeloid Leukemia
Categories: Heterocyclic Compounds, 1-RingSynonyms: {(3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-methyl-1-[ (2S)-3 -methyl-1-(propan-2- ylsulfonyl)butan-2-yl]-2-oxopiperidin-3-yl}acetic acidMRK-003
go.drugbank.com/drugs/DB17015ExperimentalMRK-003 is a potent and selective γ-secretase inhibitor developed by Merck. It is the preclinical analog of [MK-0752], a drug in clinical development.[A252682]
Categories: Heterocyclic Compounds, 1-RingSynonyms: (1'R,4R)-2-(2,2,2-trifluoroethyl)-5'-[(E)-3-[4-(trifluoromethyl)piperidin-1-yl]prop-1-enyl]spiro[1,2,5-thiadiazolidine-4,13'-tricyclo[8.2.1.03,8]trideca-3(8),4,6-triene] 1,1-dioxideTrihexyphenidyl
go.drugbank.com/drugs/DB00376ApprovedInvestigational[L31843] It has largely been replaced by drugs such as [levodopa].[L31843] Trihexyphenidyl was granted FDA approval on 13 May 1949.[L31768] … [L31773,L31778] Its discovery was published in 1949 in a study looking for drugs with antispasmodic activity.
Categories: Heterocyclic Compounds, 1-RingInternational brands: Ea TenMoexipril
go.drugbank.com/drugs/DB00691ApprovedInvestigationalMoexipril is a non-sulfhydryl containing precursor of the active angiotensin-converting enzyme (ACE) inhibitor moexiprilat. It is used to treat high blood pressure (hypertension). … It works by relaxing blood vessels, causing them to widen. Lowering high blood pressure helps prevent strokes, heart attacks and kidney problems.
Mixtures: UNIRETIC 15 MG/ 25 MG FILM KAPLI TABLET, 30 ADET, UNIRETIC 7,5 MG/ 12.5 MG FILM KAPLI TABLET, 30 ADETCategories: Heterocyclic Compounds, 2-RingTK-112690
go.drugbank.com/drugs/DB18822InvestigationalSynonyms: O2,2'-anhydro-5-methyluridine, 6h-furo(2',3':4,5)oxazolo(3,2-a)pyrimidin-6-one, 2,3,3a,9a-tetrahydro-3-hydroxy-2-(hydroxymethyl)-7-methyl-, (2r,3r,3as,9ar)-(5S)-5-(2-amino-2-oxoethyl)-4-oxo-N-[(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)methyl]-3,4,5,6,7,8-hexahydro[1]benzothieno[2,3-d]pyrimidine-2-carboxamide
go.drugbank.com/drugs/DB07397ExperimentalSynonyms: (5S)-5-(2-amino-2-oxoethyl)-4-oxo-N-[(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)methyl]-3,4,5,6,7,8-hexahydro[1]benzothieno[2,3-d]pyrimidine-2-carboxamideRibavirin
go.drugbank.com/drugs/DB00811ApprovedInvestigationalThe dual therapy was administered for 48 weeks in patients with genotype 1, 4, 5, and 6, and 24 weeks in patients with genotype 2 and 3 [A19626]. … Combination therapy of ribavirin and [DB00008] results in the SVR of 44% in patients with genotype 1 infection and 70% in patients with genotype 2-6.
Mixtures: Rebetron Ready To Use Solution (albumin(human)free) (6000000 Iu/ml and 200mg Capsules), Rebetron Solution (albumin (human) Free) (18 Miu Multi-dose Pen / 200mg Capsules)Categories: Treatments for Hepatitis C